三阴型乳腺癌新辅助化疗的疗效观察

Effect observation of neoadjuvant chemotherapy for triple negative breast cancer

目的探讨TEC方案在三阴型乳腺癌新辅助化疗中的疗效。方法回顾性分析118例接受TEC方案新辅助化疗的乳腺癌患者,三阴型乳腺癌患者52例,非三阴型乳腺癌患者66例,观察两组患者化疗疗效和Ki67的表达情况。结果 Ki67高表达者所占比例在三阴组明显高于非三阴组(分别为78.9%,53.0%,P=0.001),三阴组Ki67高表达者比低表达者更易获得pCR(P=0.022)。三阴组pCR、CR、OPR、ORR、SD以及PD分别为28.8%、36.5%、51.9%、88.5%、9.6%以及1.9%,非三阴组分别为7.6%、17.3%、47.0%、62.1%、34.8%以及3%,其中两组pCR、CR、ORR以及SD差异均有统计学意义(P<0.05)。结论 TEC方案应用于三阴型乳腺癌新辅助化疗能获得较高的pCR率,Ki67高表达在三阴型乳腺癌中更多见,且更能够获得pCR。

Objective To investigate the curative effect of TEC regimen of neoadjuvant chemotherapy for triple negative breast cancer. Methods 118 breast cancer patients of receiving TEC regimen of neoadjuvant chemotherapy were reviewed. There were 52 patients with triple negative breast cancer and 66 patients with non-triple negative breast cancer. The curative effect and expression of Ki67 for two groups was observed. Results The rate of high expression Ki67 in the triple negative group was higher than non-triple negative group （78.9% vs.53.0%, P=0.001）; for triple negative group, the patients with higher expression of Ki67 could be easier to get pCR than patients with lower expression of Ki67 （P=0.022）. The pCR, CR, OPR, eRR, SD and PD in triple negative group was 28.8%, 36.5%, 51.9%, 88.5%, 9.6% and 1.9% while the rate in non-triple negative group was 7.6%, 17.3%, 47.0%, 62.1%, 34.8% and 3%; The pCR, CR, eRR and SD for two groups was significantly different （P 〈 0.05）. Conclusion The application of TEC regimen can get the higher pCR rate in the neoadjuvant chemotherapy of triple negative breast cancer. The high expression of Ki67 is often seen in the triple negative breast cancer and easier to get pCR.